Hematology Approved Deal Benchmarks — Europe (2026)

Understanding Hematology Deal Benchmarks at Approved

Approved Hematology licensing deals in Europe territory command a median upfront payment of $1.3B, with values ranging from $978M at the low end to $1.6B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the hematology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.7B to $3.6B, with a median of $3.1B. Royalty rates for hematology assets at this stage typically fall between 12% and 21.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.